

# Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis

Trivedi, Palak; Scalera, Irene; Slaney, Emma; Laing, Richard; Gunson, Bridget; Hirschfield, Gideon; Schlegel, Andrea; Ferguson, James W.; Muiesan, Paolo

DOI:

[10.1016/j.jhep.2017.06.027](https://doi.org/10.1016/j.jhep.2017.06.027)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Trivedi, P, Scalera, I, Slaney, E, Laing, R, Gunson, B, Hirschfield, G, Schlegel, A, Ferguson, JW & Muiesan, P, 2017, 'Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis', *Journal of Hepatology*, vol. 67, no. 5, pp. 957-965. <https://doi.org/10.1016/j.jhep.2017.06.027>

[Link to publication on Research at Birmingham portal](#)

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## Accepted Manuscript

Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis

Palak J. Trivedi, Irene Scalera, Emma Slaney, Richard W. Laing, Bridget Gunson, Gideon M. Hirschfield, Andrea Schlegel, James Ferguson, Paolo Muiesan


PII: S0168-8278(17)32135-9  
DOI: <http://dx.doi.org/10.1016/j.jhep.2017.06.027>  
Reference: JHEPAT 6585

To appear in: *Journal of Hepatology*

Received Date: 17 November 2016  
Revised Date: 23 June 2017  
Accepted Date: 27 June 2017

Please cite this article as: Trivedi, P.J., Scalera, I., Slaney, E., Laing, R.W., Gunson, B., Hirschfield, G.M., Schlegel, A., Ferguson, J., Muiesan, P., Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis, *Journal of Hepatology* (2017), doi: <http://dx.doi.org/10.1016/j.jhep.2017.06.027>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



# Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis.

Palak J. Trivedi,<sup>1,2 \*</sup> Irene Scalera,<sup>2 \*</sup> Emma Slaney,<sup>2</sup> Richard W. Laing,<sup>1,2</sup> Bridget Gunson,<sup>1,2</sup> Gideon M. Hirschfield,<sup>1,2</sup> Andrea Schlegel,<sup>2,3</sup> James Ferguson<sup>1,2 \*\*</sup> and Paolo Muiesan<sup>1,2,4 \*\*</sup>

1. National Institute for Health Research (NIHR) Birmingham Liver Biomedical Research Centre (BRC), Institute of Immunology and Immunotherapy, University of Birmingham (UK)
2. Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham (UK)
3. Department of Surgery and Transplantation, University Hospital Zürich, Zürich, Switzerland
4. Department of Liver Surgery, Birmingham Children's Hospital NHS Foundation Trust, Birmingham (UK)

\* Joint first author

\*\* Joint senior author

Address for correspondence:

[James.Ferguson@uhb.nhs.uk](mailto:James.Ferguson@uhb.nhs.uk)

[Paolo.Muiesan@uhb.nhs.uk](mailto:Paolo.Muiesan@uhb.nhs.uk)

**Keywords:** Primary sclerosing cholangitis; liver transplantation; ulcerative colitis; ischaemic-type biliary lesion; non-anastomotic biliary stricture; hepatic artery thrombosis; non-heartbeating donor; risk stratification.

<b>Word count (inc. abstract, tables, figure legends and references):</b>	5,992
<b>Number of Tables:</b>	3
<b>Number of Figures:</b>	4
<b>Number of Supplementary Tables:</b>	6
<b>Number of Supplementary Figures:</b>	5

**Conflicts of interest:**

None.

**Funding support:**

PJT, BG and GMH received funding from the NIHR BRU.

**Disclosures:**

This article is independent research supported by the NIHR Birmingham Liver Biomedical Research Unit. The views expressed in this publication are of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health.

**Author contribution statement:**

PJT conducted data extraction, statistical analysis, and prepared the first and subsequent manuscript drafts to submission.

IS participated in data extraction, quality control, provided critical input into data analysis and approved the final manuscript to submission.

ES and RWL participated in data extraction and approved the final manuscript to submission.

BG maintains the prospectively collected liver transplant database at the University Hospitals Birmingham NHS Foundation Trust, provided critical insight into data analysis, and approved the manuscript to submission.

AS and GMH provided critical insight into data analysis, presentation, and approved the manuscript to submission.

JF and PM conceived the idea, approved study design and approved the manuscript to submission.

**LAY SUMMARY**

This study examines the impact of liver transplantation in primary sclerosing cholangitis (PSC) with organs donated after circulatory death (DCD), compared to donation after brainstem death (DBD). We show that in appropriately selected patients, the outcomes for DCD transplantation mirror those using DBD livers, with no significant differences in complication rate, patient survival or transplanted liver survival. In an era of organ shortage and increasing wait-list times, DCD livers represent a potential treatment option for transplantation in PSC.

**ABSTRACT**

**Background and aim:** Primary sclerosing cholangitis (PSC) is a progressive fibro-inflammatory cholangiopathy for which liver transplantation is the only life-extending intervention. These patients may benefit from accepting liver donation after circulatory death (DCD), however their subsequent outcome is unknown.

**Methods:** Clinical outcomes were prospectively evaluated in PSC patients undergoing transplantation from 2006 to 2016 stratified by donor type (DCD,  $n=35$  vs. donation after brain death [DBD],  $n=108$ ).

**Results:** In liver transplantation for PSC; operating time, days requiring critical care support, total ventilator days, incidence of acute kidney injury, need for renal replacement therapy (RRT) or total days requiring RRT were not significantly different between DCD vs. DBD recipients. Although the incidence of ischaemic-type biliary lesions was greater in the DCD group (incidence rate [IR]: 4.4 vs. 0 cases/100-pt.-yrs;  $p<0.001$ ) there was no increased risk of post-transplant biliary strictures overall (hazard ratio [HR]: 1.20, 0.58–2.46;  $p=0.624$ ), or in sub-analysis specific to anastomotic strictures or recurrent PSC, between donor types. Graft loss and mortality rates were not significantly different following transplantation with DCD vs. DBD livers (IR: 3.6 vs. 3.1 cases/100-pt.-yrs,  $p=0.34$ ; and 3.9 vs. 4.7,  $p=0.6$ ; respectively). DCD liver transplantation in PSC did not impart a heightened risk of graft loss (HR: 1.69, 0.58–4.95,  $p=0.341$ ) or patient mortality (0.75, 0.25–2.21,  $p=0.598$ ).

**Conclusion:** Transplantation with DCD (vs. DBD) livers in PSC does not impact graft loss or patient survival. In an era of organ shortage, DCD grafts represent a viable therapeutic option for liver transplantation in PSC patients.

## INTRODUCTION

Primary sclerosing cholangitis (PSC) is a progressive fibro-inflammatory cholangiopathy stigmatised by a disproportionate impact on young patients [1,2]. Presently, liver transplantation is the only proven life-extending intervention, and PSC now accounts for 10 – 15% of all liver transplant activity within Europe [3–5]. In parallel, the overall number of patients with chronic liver disease on an active liver transplant register is increasing globally [4–6], without an appropriate rise in the donor pool [7]. A challenge more specific to PSC, is that patients may suffer complications inadequately represented by the model for end-stage liver disease (MELD) score; such as intractable pruritus, recurrent ascending cholangitis, and reduced overall quality of life [8]. Consequently, the number of PSC patients who die or are withdrawn from a transplant waiting list due to clinical deterioration is rising, and now approximates 20% [9]. This group of invariably young individuals may have their life saved in the event of timely donor availability.

Donation after brain death (DBD) is the practice of choice in liver transplantation, although the increasing demand for organs has furthered interest in using grafts donated after circulatory death (DCD). Indeed, the advances in graft preservation, immunosuppression and operative techniques have significantly improved clinical outcomes following DCD grafting [10]. However, DCD livers are still used prudently [11], given the risk of acute kidney injury (AKI) and ischaemic type biliary lesions (ITBL) [12–16]. The latter are defined radiologically, as biliary strictures and dilatations occurring in the absence of hepatic artery stenosis or thrombosis, portal thrombosis, chronic ductopenic rejection, and recurrent PSC [14,17]; and associated



clinically with significant patient morbidity, a need for multiple biliary interventional procedures and repeated hospital admissions [12,18].

The precise pathogenic mechanisms leading to ITBL are unknown, but postulated to involve ischaemia reperfusion injury (IRI), microvessel thrombosis and impaired cholangiocyte regeneration [14]. In transplantation for PSC more specifically, we also observe a high incidence of post-transplant biliary strictures attributable to recurrent disease [19,20]. Development of the latter has also been attributed to poor quality in donor organs [21,22], and a proposal that IRI itself can lead to a *de novo* autoimmune cascade and recurrence of PSC in the transplanted liver. Such hypothesis suggests existence of a common mechanistic pathway in the pathogenesis of biliary strictures post liver transplantation [21,23]. Furthermore, cholangiographic features of ITBL and recurrent PSC cannot be easily distinguished, and often reported collectively as non-anastomotic stricturing disease [19].

The University Hospitals Birmingham NHS Foundation Trust (UHB) contributes 25% of all liver transplant activity in the United Kingdom (UK); and in contrast to several other centres, our decline rate for offered DCD liver grafts was only ~20% by 2016 [5]. We select recipients for a DCD graft who are deemed ‘low-risk,’ for instance patients with MELD scores enough to warrant transplantation, but too low to reach priority on the waiting list. This contrasts to institutional policy elsewhere, wherein high MELD scoring patients are preferentially selected due to the survival benefit from early transplantation being greatest for this group [24–26]. However, our experience as well as that of certain others, is that patients having a low MELD score are more likely to achieve survival benefit with a DCD liver compared to prolonged transplant wait-list times; whereas those with a high-risk phenotype experience an

increased rate of graft failure and post-transplant complications [10,27,28]. Furthermore, all DCD retrievals are derived from controlled donors (Maastricht III) [29] and we have shown that with appropriate recipient selection and maintaining low ischaemic times, DCD livers yield outcomes similar to DBD transplantation [10]. Nevertheless, liver transplantation for PSC across many centres is restricted to the usage of DBD grafts [19], due to apprehensions of post-transplant biliary complications. Given that the incidence of PSC is rising [30], while the prevalence of an 'ideal' donation pool continues to decline, the usage of liver grafts arising from DCD donors seems unavoidable in clinical practice. Thus, the aim of this study was to determine the clinical impact of using liver grafts donated after circulatory death in patients specifically undergoing transplantation for PSC.

## PATIENTS AND METHODS

### Study population

We reviewed a prospectively collected, well-characterised database of all adult patients undergoing liver transplantation since the date of our first DCD transplant in a PSC patient (February 2006) and up until January 2016. The hospital transplant database is maintained prospectively and contains information on the donor, the recipient, the retrieval process, the peri-operative period, complications and follow-up, as detailed elsewhere [10]. In order to ensure robustness, accuracy and completeness of data for our PSC cohort, the transplant database was cross-referenced with an independently accrued registry of all patients having previously attended or under current follow-up of the Birmingham PSC clinic since September 1983. Only patients transplanted between 2006 and 2016 were selected for this study.

### Clinical endpoints

The 'time-dependent' clinical endpoints for our study were as follows:

- A) Graft loss and patient mortality (primary study endpoint).
- B) Primary vascular injury; specifically hepatic artery thrombosis (HAT) and hepatic artery stenosis (HAS) – evident on contrasted computed tomography (CT), magnetic resonance imaging (MRI) or dedicated angiography.
- C) Biliary stricturing disease; with sub-analysis specifically for non-anastomotic strictures – evident on cholangiography (either magnetic resonance or endoscopic retrograde cholangiopancreatography; MRCP or ERCP, respectively). When referring to non-anastomotic biliary strictures collectively, this pertains to lesions developing in the absence of ABO incompatibility, chronic rejection or hepatic artery compromise, i.e. focussing on ITBL and recurrent PSC.

The need and type of interventions required following development of vascular or biliary complications were classified as endoscopic/radiological, reconstructive surgery and need for re-transplantation. Post-operative complications were also documented according to the Clavien–Dindo grading system (IIIa and IIIb), and when a patient required multiple procedures the level of highest intervention was chosen for analysis [31].

Patients were censored at the date of last follow-up if they did not meet the clinical endpoint in question. In addition, primary graft non-function, bile leaks or acute kidney injury (AKI) were assessed as peri-operative ‘categorical’ endpoints with a binary outcome measure. The latter was defined with reference to the ‘Risk, Injury, Failure, Loss, End-stage kidney disease’ (RIFLE) criteria [32].

### **Statistical analysis**

Data are presented using the median and interquartile range (IQR) for continuous variables. The non-parametric Mann-Whitney U-test was used to determine whether significant differences existed between groups. Differences in nominal data were compared by Fisher’s exact test. A  $p$  value of  $<0.05$  was deemed statistically significant.

Clinical outcomes’ analysis was performed through Kaplan-Meier survivorship estimates, and significant differences between groups assessed by Log-rank testing. The proportion of clinical events are presented as cumulative incidence (%) and as incidence rates (IR) per 100-patient-years with respective confidence intervals (95% CI). Additionally, Cox proportional hazards models were fit in order to assess the

impact of individual covariates on the instantaneous rate of respective events (hazard ratios [HR]). All data were analysed using IBM® SPSS® v.23.0 (Armonk, NY: IBM Corp.)

Completeness, plausibility and validity of the data were independently verified (by PJT, IS, RL and ES), including personalised objective review of all historical medical charts. Local regulatory board approval was obtained prior to study initiation and database/chart review (CAB-04186-12 and CARMS-02246).

## RESULTS

### Characteristics of the patient population

Over a ten-year period, 143 patients with PSC undergoing transplantation at our unit received either a DBD or DCD liver graft. The majority were men (71.3%), with a median age at time of transplant of 49 years (IQR: 35 – 60), and a pre-existing history inflammatory bowel disease (IBD; 70.6%) (**Supplementary Table 1**). Observing this cohort in its entirety, 34 patients experienced a clinically significant episode prior to the end of our study; specifically graft loss (n=16) and/or death (n=22), yielding a cumulative follow-up till first clinical event of 457-patient-years (IR: 7.45, 95% CI: 6.60 – 8.82 events per 100-patient-years).

### Peri-operative course of PSC-DCD versus PSC-DBD liver transplant recipients

Within our PSC cohort, 35 patients received liver donation after circulatory death. Characteristics were similar between DBD and DCD groups, although recipients of the latter were observed to have lower MELD scores, shorter warm ischaemic times (WIT / implantation time) and shorter donor cold ischaemic times (CIT) (**Supplementary Table 1**). The median donor functional warm ischaemic time for DCD livers was 20 minutes.

Comparing donor groups, there were no significant differences in the median duration of surgery, transfusion requirements, duration of intensive care unit (ICU) stay or duration of hospital stay in total. Post-operative bile leaks were more common in recipients of a DCD liver, who also trended an increased risk of renal injury. These differences were not, however, statistically significant, even after restricting the analysis to transplantation using non-split livers (**Table 1**).

### **Transplantation in PSC is associated with a high incidence of vascular events**

Overall, 24.5% of PSC patients ( $n=35$ ) developed a vascular complication post-transplantation; with a heightened risk in DCD recipients that reached statistical significance when excluding split donor grafts (vs. all DBD grafts, HR: 1.77, 0.88 – 3.57,  $p=0.110$ ; vs. non-split DBD grafts only, HR: 2.52, 1.16 – 5.46,  $p=0.020$ ). Vascular complications were predominantly hepatic artery stenosis or hepatic artery thrombosis (**Supplementary Table 2** and **Supplementary Figure 1**), with lesser contribution from isolated cases of hepatic artery aneurysms, portal vein stenosis, and branch portal vein occlusion (data not shown).

We observed that approximately 9% of all transplanted PSC patients developed HAT irrespective of donor type, with the highest incidence in those having pre-existing IBD (**Supplementary Figure 2**). However, the risk of developing HAT was not significantly greater in DCD vs. DBD donor types (HR: 1.09, 0.30 – 4.00,  $p=0.895$ ) even after excluding transplantation utilising split liver grafts (HR: 1.23, 0.32 – 4.80,  $p=0.767$ ).

### **Incidence of post-transplantation biliary strictures is independent of donor type**

In our PSC cohort, 31.5% of transplanted patients ( $n=45$ ) developed recurrent biliary strictures, 6 of which were attributed to hepatic artery stenosis (DBD=3 vs. DCD=3,  $p=0.157$ ); with the remainder unrelated to vascular injury (**Supplementary Table 3**, **Figure 1**, **Figure 2** and **Figure 3**).

Approximately 15% of PSC patients underwent biliary reconstruction via duct-to-duct anastomosis, which was associated with a shorter median operating time compared to

choledochojejunostomy (4.2 [3.4 – 4.8] hrs. vs. 5.0 [4.1 – 5.8] hrs.  $p=0.033$ ). In all 21 cases, the choice of duct-to-duct anastomosis was made when the recipient biliary tree was free from extra-hepatic disease, including 2 patients with significant bowel wall oedema, 1 individual with prior small bowel resection (due to Crohn's disease) and 2 with extensive intra-abdominal adhesions. No patient with duct-to-duct anastomosis developed post-transplant biliary malignancy.

The incidence of non-anastomotic biliary strictures overall (NAS), as well as event-free survival at 6- and 12-months was not significantly different when stratified by donor type (**Figure 1**). Although duct-to-duct anastomoses were more common in our DCD group (**Table 1**), this did not confer an increased risk of NAS (**Supplementary Figure 3A and B**). Reciprocally, there was no increased risk of developing NAS in patients with a Roux-en-Y choledochojejunostomy in DCD vs. DBD transplantation (**Supplementary Figure 3C and D**).

Observing our PSC cohort in its entirety, NAS were most often classified as disease recurrence if manifest following DBD transplantation (16.7%), compared to ITBL in DCD recipients (11.4%) (**Supplementary Table 3**). Whilst the incidence of ITBL was significantly greater using DCD livers (**Figure 2** and **Figure 3**) the overall risk of developing any post-transplantation biliary stricture (HR: 1.20, 0.58 – 2.46,  $p=0.624$ ), in addition to the number of patients needing intervention, was not significantly greater when compared with DBD grafts (**Supplementary Table 3** and **Supplementary Table 4**).

Non-anastomotic biliary strictures in keeping with ITBL ( $n=4$ ) developed within the first year following transplantation, with a median time-to-event of 116 days in the



affected group; range 27 – 371 days. By contrast, patients who developed recurrent PSC ( $n=20$ ) demonstrated a significantly longer median time-to-event of 871.5 days; range 118 – 2163 days ( $p=0.018$ ; Mann-Whitney test). No incidence of recurrent PSC developed within 90 days, and the only 2 cases diagnosed in our DCD group were identified at 427 days and 1083 days after transplantation. Amongst the total group with NAS ( $n=24$ ), Histopathological assessment was available for 10 patients; including all who manifest early biliary lesions in the post-transplant course (within 6 months) despite receiving a DBD liver. In all of the latter, histology supported a diagnosis of PSC recurrence; complementary to clinical suspicion, timing of onset of biliary strictures and cholangiographic assessment.

#### **Graft loss and patient mortality rates are similar for DCD versus DBD recipients**

With regard to our primary endpoint, we observed no significant differences in graft or patient survival times between donor types, even after excluding recipients of split livers (**Table 2** and **Figure 4**). Notably, there was no increased risk of graft loss (HR: 1.69, 95% CI: 0.58 – 4.95;  $p=0.341$ ), mortality risk (HR: 0.75, 95% CI: 0.25 – 2.21;  $p=0.598$ ), or graft loss/mortality as a combined endpoint (HR: 1.24, 95% CI: 0.56 – 2.66;  $p=0.583$ ) with DCD versus DBD liver transplantation in PSC (**Table 2**).

#### **Outcomes for DCD transplantation in PSC are akin to non-PSC DCD recipients**

Next, we compared the post-transplant outcomes in our PSC cohort versus that observed for other aetiologies (**Supplementary Table 5** and **Supplementary Table 6**). The overall rate of graft loss was greater following liver transplantation for PSC (**Table 3** and **Supplementary Figure 4**), albeit with no significant differences in patient mortality, or graft loss/mortality as a combined endpoint.

The proportion of patients developing HAT was greater in our PSC vs. non-PSC liver transplant cohort (9.1% vs. 4.8%, respectively;  $p=0.046$ ). However, the incidence was not significantly different between DCD recipients of PSC vs. non-PSC aetiology (IR: 3.4 [95% CI: 2.6 – 5.3] vs. 3.0 [95% CI 2.6 – 3.4];  $p=0.775$ ). Although the incidence of NAS (overall) was similar between PSC DCD vs. non-PSC DCD cohorts, a proportionally greater event rate was observed in PSC patients when restricting analysis to lesions manifesting after the first 12 months following transplantation (**Supplementary Figure 5A**), indicative of the burden of recurrence. However, the incidence rate of ITBL, specifically, was not significantly different between groups receiving a DCD liver (**Supplementary Figure 5A**).

## DISCUSSION

Herein, we describe the clinical course following liver transplantation across a contemporary cohort of PSC patients stratified by donor type; specifically DCD versus DBD graft recipients. In so doing, we found no significant differences in transfusion requirement, need for organ support post-transplant, or length of hospital stay between groups. Whilst the incidence of ITBL was heightened in DCD recipients, the risk of AKI, HAT, or biliary strictures overall, was not significantly increased when compared with the DBD group over time. Perhaps most apparent, was the finding that DCD versus DBD transplantation did not adversely affect recipient or graft survival in PSC; and whilst the rate of graft loss was significantly greater compared to non-PSC patients, this was not confined to a particular donor type.

As an aetiology of chronic liver disease, the burden of PSC on younger patients is substantial, with a median age of transplantation below 50 years. Thus, there is a need to maximise the number of 'life-years' gained after transplantation, and clinicians who manage PSC strive to provide patients with the best graft possible. Unfortunately the divide between an optimum donation pool and the number of patients who require liver transplantation is increasing. The transplant community must therefore capitalise on the reach of DCD grafts in response to the rising burden not just of PSC [30], but also of chronic liver disease in general [33]. In the UK, the number of patients on the active liver transplant register has more than doubled in the last ten years, and in response there has been an exponential rise in the usage of DCD grafts [5,6]. Conversely, the United Network for Organ Sharing (UNOS) database from North America indicates that donation after circulatory death increases the odds of liver non-use by four-fold [11]. The increasing reluctance to use DCD livers largely

reflects the perception that post-transplant outcomes are worse, in particular the development of ITBL [12–14,24,34,35].

Such apprehensions may be heightened particularly in patients with PSC, who harbour an additive risk of post-transplant biliary strictures related to recurrent disease [19–21]. The morphological features of recurrent PSC are often difficult to distinguish from biliary strictures due to ITBL, and presently there is no single diagnostic tool permitting accurate differentiation with absolute certainty. In addition to the impact of marginal donor organ quality [14], ITBL develops most commonly in the first 6 – 12 months following transplantation [36]. This contrasts with reports of PSC recurrence, which tends to manifest after the first year [37]. Histopathology may also complement clinical and radiological suspicion; for instance, widespread ulceration and necrosis of the large bile duct branches as well as arteriolonecrosis are described for ITBL, but such features are infrequent in PSC [38,39].

With these caveats in mind, we observed no significant difference in incidence of NAS overall between PSC DBD vs. PSC DCD patients across multiple time points. However, strictures that were felt more in keeping with ITBL developed exclusively in the first 12 months and concordant with receiving a DCD liver. In any event the number requiring interventional procedures – a major determinant of quality of life – was similar between donor groups, even in a sub-analysis of intervention type. This has implications for the appropriate counselling of patients who are at risk of developing post-transplant stricturing disease, although longer-term, multi-centre studies are required to validate our experience.

The traditional method of biliary anastomosis in liver transplantation for PSC is Roux-en-Y choledochojejunostomy [40]; and whilst some investigators report success with choledochoduodenostomy, the approach is not universally favoured given concerns over duodenal leaks and overall biliary complications [41,42]. Additionally, 21 patients in our cohort underwent duct-to-duct biliary reconstruction and in all cases this was when the recipient common bile duct was free of visible disease. Historically, duct-to-duct anastomosis was not opted for in PSC transplantation given the perceived risk of recurrent biliary strictures [40], and theoretically, malignant degeneration. However, more contemporary data including that from meta-analyses indicate there is no increased risk when compared to Roux-en-Y choledochojejunostomy [43–47]; findings validated convincingly in our study. Duct-to-duct anastomosis more effectively restores the natural anatomy and function of the biliary tree, maintains normal sphincter function (putatively reducing the incidence of cholangitis episodes), and facilitates easier accessibility to the bile ducts by ERCP post-transplant. This is highly relevant for PSC patients, given the incidence with which NAS occur. By contrast, there may arise circumstances wherein Roux-en-Y anastomosis is less favourable, for instance in patients with previous surgery resulting in a shortened small bowel, extensive intra-abdominal adhesions, small bowel oedema due to portal hypertension, or if there has been prolonged portal vein clamping during the transplant procedure.

Pathophysiological understanding of non-anastomotic biliary stricturing is incomplete, although the risks for developing ITBL and recurrent PSC are probably linked to donor graft quality and factors inherent to the recipient, respectively. However, overlapping mechanistic insults have been proposed, including putative micro-angiopathic aetiology and a ‘toxic bile’ hypothesis [14,23,48–50], illustrating

how a multitude of biologic pathways result in a common phenotypic manifestation. In any event, no evidence-based therapy has been consistently proven to improve graft survival for either entity, and re-transplantation may be indicated for both. Whilst it can be argued that management strategies should differ, our threshold for intervention (including the need for re-transplantation) remains driven by the extent/distribution of biliary stricturing, severity of graft dysfunction, and/or the burden of recurrent biliary sepsis; not whether strictures are formally labelled as ITBL or PSC recurrence.

With regard to clinical outcome, the literature presents a conflicting picture, with multi-centre registries indicating a relatively high graft failure rate with DCD livers [34,35]; whereas smaller, yet ‘high-volume’ single-centre studies indicate similar graft and patient survival following DBD transplantation [10,51–53]. Furthermore, meta-analyses of clinical outcomes following DCD liver transplantation highlight a significant yet unexplained difference in effect size between individual contributing units [13,54]. This may explain our discrepant findings compared with the UNOS report, which demonstrated a higher risk of graft loss following DCD transplantation in PSC despite maintaining similar donor functional warm ischaemic times (FWIT) [22]. Furthermore, DCD retrievals in the UK take place almost exclusively with the use of ‘controlled’ retrievals (according to Maastricht criteria), and in our centre provided to patients with low MELD scores. This contrasts with certain other European countries and the United States, where both controlled and uncontrolled DCD retrievals may be utilised [55].

Notably, a greater incidence of graft loss was observed in PSC patients overall, despite this group having more favourable donor and recipient characteristics than

their non-PSC counterparts; including younger donor and recipient age, lower donor and recipient body mass index (BMI), and shorter WIT and CIT. These findings suggest a more general predisposition to the development of post-transplant vascular and biliary injury. However, the incidence rate of HAT with DCD livers was not greater for PSC patients, rather increased specifically in the cohort with a history of pre-existing IBD. The latter harbours a well recognised association with PSC, and also with increased platelet activation and an increased risk of thromboembolism [56]. Our study is not without limitation. Despite being the largest single-centre experience utilising DCD liver transplantation in PSC patients, external independent and prospective validation is of critical importance. Additionally, the lack of protocol cholangiographic / angiographic surveillance post-transplantation is caveat across most studies determining outcomes following liver transplantation, including those from our own centre. In this regard, it is conceivable that the sub-clinical incidence of vascular events and biliary strictures was higher than actually reported. Finally, it must be recognised that DCD liver transplantation is an evolving practice, and longer-term patient and graft survival impact have yet to be determined.

**In conclusion, the frequency of post-transplant biliary strictures in PSC does not significantly differ between donor types, although DCD recipients are more prone to early, ischaemic-type biliary lesions. However, overall patient and graft survival rates are not significantly different between PSC-DCD and PSC-DBD groups. Given the era of organ shortage, DCD liver transplantation represents a viable life-extending intervention in an appropriately selected patient population.**

## REFERENCES

- 1 Hirschfield GM, *et al.* Primary sclerosing cholangitis. *Lancet* 2013;**382**:1587–99.
- 2 Boonstra K, *et al.* Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. *Hepatology* 2013;**58**:2045–2055.
- 3 Patkowski W, *et al.* Orthotopic liver transplantation for cholestatic diseases. *Hepatology* 2010;**57**:605–10.
- 4 Fosby B, *et al.* Liver transplantation in the Nordic countries - An intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982-2013. *Scand J Gastroenterol* 2015;**50**:797–808.
- 5 NHS Blood and Transplant Annual report on liver transplantation 2015/2016.  
2016;;[http://www.odt.nhs.uk/pdf/organ\\_specific\\_report\\_liver\\_2016.pdf](http://www.odt.nhs.uk/pdf/organ_specific_report_liver_2016.pdf).
- 6 Johnson RJ, *et al.* Organ donation and transplantation in the UK-the last decade: a report from the UK national transplant registry. *Transplantation* 2014;**97 Suppl 1**:S1–27.
- 7 Wertheim JA, *et al.* Major challenges limiting liver transplantation in the United States. *Am J Transplant* 2011;**11**:1773–84.
- 8 Dyson JK, *et al.* Unmet clinical need in autoimmune liver diseases. *J Hepatol* 2015;**62**:208–18.



- 9 de Vries A, *et al.* Liver transplantation waiting list mortality in PSC patients is low as compared to non-PSC patients and consistent across laboratory MELD and MELD exception candidates: a nationwide study in the Netherlands. *Hepatology* 2015;**62**:S241A.
- 10 Laing RW, *et al.* Liver transplantation using grafts from donors after circulatory death: A propensity-matched study from a single centre. *Am J Transplant* 2016;**16**:1795–804.
- 11 Orman ES, *et al.* Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death. *Liver Transpl* 2013;**19**:59–68.
- 12 Foley DP, *et al.* Biliary complications after liver transplantation from donation after cardiac death donors: an analysis of risk factors and long-term outcomes from a single center. *Ann Surg* 2011;**253**:817–25.
- 13 O'Neill S, *et al.* A meta-analysis and meta-regression of outcomes including biliary complications in donation after cardiac death liver transplantation. *Transpl Int* 2014;**27**:1159–74.
- 14 Hessheimer AJ, *et al.* Can we prevent ischemic type biliary lesion in DCD liver transplantation? *Liver Transpl* 2016;
- 15 Leithead JA, *et al.* Donation after cardiac death liver transplant recipients have an increased frequency of acute kidney injury. *Am J Transplant* 2012;**12**:965–75.

- 16 Leithead JA, *et al.* The evolving use of higher risk grafts is associated with an increased incidence of acute kidney injury after liver transplantation. *J Hepatol* 2014;**60**:1180–6.
- 17 Frongillo F, *et al.* Factors Predicting Ischemic-Type Biliary Lesions (ITBLs) After Liver Transplantation. *Transplant Proc* 2012;**44**:2002–4.
- 18 Heidenhain C, *et al.* Incidence of and risk factors for ischemic-type biliary lesions following orthotopic liver transplantation. *Transpl Int* 2010;**23**:14–22.
- 19 Hildebrand T, *et al.* Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis: Biliary Strictures and PSC Recurrence. *Liver Transpl* 2016;**22**:42–52.
- 20 Ravikumar R, *et al.* Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. *J Hepatol* 2015;**63**:1139–46.
- 21 Alabraba E, *et al.* A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. *Liver Transpl* 2009;**15**:330–40.
- 22 Sundaram V, *et al.* Donation after cardiac death liver transplantation in primary sclerosing cholangitis: proceed with caution. *Transplantation* 2015;**99**:973–8.
- 23 Abdalian R, *et al.* Sclerosing cholangitis: a focus on secondary causes. *Hepatology* 2006;**44**:1063–74.

- 24 Mathur AK, *et al.* Donation after cardiac death liver transplantation: predictors of outcome. *Am J Transplant* 2010;**10**:2512–9.
- 25 Croome KP, *et al.* Improving National Results in Liver Transplantation Using Grafts From Donation After Cardiac Death Donors. *Transplantation* 2016;**100**:2640–7.
- 26 Bellingham JM, *et al.* Donation after cardiac death: a 29-year experience. *Surgery* 2011;**150**:692–702.
- 27 Skaro AI, *et al.* The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: the untold story. *Surgery* 2009;**146**:543-552-553.
- 28 McLean KA, *et al.* Decision modelling in donation after circulatory death (DCD) liver transplantation. *Liver Transpl* Published Online First: 27 December 2016.
- 29 Kootstra G, *et al.* Categories of non-heart-beating donors. *Transplant Proc* 1995;**27**:2893–4.
- 30 Boonstra K, *et al.* Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review. *J Hepatol* 2012;**56**:1181–8.
- 31 Dindo D, *et al.* Classification of Surgical Complications. *Ann Surg* 2004;**240**:205–13.
- 32 Aksu Erdost H, *et al.* Acute Renal Injury Evaluation After Liver Transplantation: With RIFLE Criteria. *Transplant Proc* 2015;**47**:1482–7.

- 33 Williams R, *et al.* Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. *The Lancet* 2014;**384**:1953–97.
- 34 Blok JJ, *et al.* Long-term results of liver transplantation from donation after circulatory death. *Liver Transpl* 2016;
- 35 Mateo R, *et al.* Risk factors for graft survival after liver transplantation from donation after cardiac death donors: an analysis of OPTN/UNOS data. *Am J Transplant* 2006;**6**:791–6.
- 36 Buis CI, *et al.* Causes and consequences of ischemic-type biliary lesions after liver transplantation. *J Hepatobiliary Pancreat Surg* 2006;**13**:517–24.
- 37 Fosby B. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. *World J Gastroenterol* 2012;**18**:1.
- 38 Hansen T, *et al.* Histological examination and evaluation of donor bile ducts received during orthotopic liver transplantation—a morphological clue to ischemic-type biliary lesion? *Virchows Arch* 2012;**461**:41–8.
- 39 Graziadei IW, *et al.* Recurrence of primary sclerosing cholangitis following liver transplantation. *Hepatology* 1999;**29**:1050–6.
- 40 Welsh FKS, *et al.* Roux-en-Y Choledochojejunostomy is the method of choice for biliary reconstruction in liver transplantation for primary sclerosing cholangitis. *Transplantation* 2004;**77**:602–4.

- 41 Bennet W, *et al.* Choledochoduodenostomy is a Safe Alternative to Roux-en-Y Choledochojejunostomy for Biliary Reconstruction in Liver Transplantation. *World J Surg* 2009;**33**:1022–5.
- 42 Schmitz V, *et al.* Surgical complications and long-term outcome of different biliary reconstructions in liver transplantation for primary sclerosing cholangitis-choledochoduodenostomy versus choledochojejunostomy. *Am J Transplant* 2006;**6**:379–85.
- 43 Damrah O, *et al.* Duct-to-duct biliary reconstruction in orthotopic liver transplantation for primary sclerosing cholangitis: a viable and safe alternative. *Transpl Int* 2012;**25**:64–8.
- 44 Wells MM, *et al.* Roux-en-Y choledochojejunostomy versus duct-to-duct biliary anastomosis in liver transplantation for primary sclerosing cholangitis: a meta-analysis. *Transplant Proc* 2013;**45**:2263–71.
- 45 Sutton ME, *et al.* Duct-to-duct reconstruction in liver transplantation for primary sclerosing cholangitis is associated with fewer biliary complications in comparison with hepaticojejunostomy. *Liver Transpl* 2014;**20**:457–63.
- 46 Pandanaboyana S, *et al.* Meta-analysis of Duct-to-duct versus Roux-en-Y biliary reconstruction following liver transplantation for primary sclerosing cholangitis. *Transpl Int* 2015;**28**:485–91.
- 47 Shamsaeefar A, *et al.* Biliary reconstruction in liver transplant patients with primary sclerosing cholangitis, duct-to-duct or Roux-en-Y? *Clin Transplant* 2017;**31**.

- 48 Aron JH, *et al.* The immunobiology of primary sclerosing cholangitis. *Semin Immunopathol* 2009;**31**:383–97.
- 49 O'Mahony CA, *et al.* Etiopathogenesis of primary sclerosing cholangitis. *Semin Liver Dis* 2006;**26**:3–21. doi:10.1055/s-2006-933559
- 50 Karimian N, *et al.* Biliary complications after orthotopic liver transplantation. *Curr Opin Organ Transplant* 2014;**19**:209–16.
- 51 Pan X, *et al.* Perioperative complications in liver transplantation using donation after cardiac death grafts: a propensity-matched study. *Liver Transpl* 2014;**20**:823–30.
- 52 Dubbeld J, *et al.* Similar liver transplantation survival with selected cardiac death donors and brain death donors. *Br J Surg* 2010;**97**:744–53.
- 53 Grewal HP, *et al.* Liver transplantation using controlled donation after cardiac death donors: an analysis of a large single-center experience. *Liver Transpl* 2009;**15**:1028–35.
- 54 Callaghan CJ, *et al.* Outcomes of transplantation of livers from donation after circulatory death donors in the UK: a cohort study. *BMJ Open* 2013;**3**:e003287.
- 55 Monbaliu D, *et al.* Liver transplantation using Donation after Cardiac Death donors. *J Hepatol* 2012;**56**:474–85.
- 56 Yoshida H, *et al.* Inflammatory bowel disease: a paradigm for the link between coagulation and inflammation. *Inflamm Bowel Dis* 2009;**15**:1245–55.

ACCEPTED MANUSCRIPT

**Table 1: Operative, peri-operative and early post-operative characteristics in the PSC liver transplant cohort**

	All patients (n=143)	DBD All grafts (n=108)	DBD Non-split grafts (n=86)	DCD (n=35)	<i>p</i> *	<i>p</i> **
<b>Duration of surgery (hrs.)</b>	4.8 (4.1–5.7)	5.0 (4.1–5.7)	4.9 (4.1–6.0)	4.8 (3.9–5.4)	0.213	0.310
<b>Duct-to-duct anastomosis</b>	21 (14.7%)	12 (11.1%)	10 (11.6%)	9 (25.7%)	0.052	0.095
<b>Total Transfusion requirements</b>						
Number needing RBC	81 (56.6%)	65 (60.2%)	51 (59.3%)	16 (45.8%)	0.119	0.226
-Volume (units)	3 (2–4)	2 (2–4)	2 (2–4)	3 (2–5)	0.343	0.264
Number needing FFP	99 (69.2%)	78 (72.2%)	62 (72.1%)	21 (60%)	0.149	0.203
-Volume (units)	6 (4–10)	6 (3–10)	6 (4–10)	8 (4–10)	0.248	0.402
Number needing platelets	51 (35.7%)	40 (37.7%)	32 (37.2%)	11 (31.4%)	0.524	0.676
-Volume (units)	10 (10–10)	10 (5–13)	10 (8–13)	10 (10–10)	0.652	0.723
Number needing cryoprecipitate	7 (4.9%)	4 (3.7%)	4 (4.7%)	3 (8.6%)	0.252	0.411
-Volume (units)	2 (1–2)	2 (2–4)	2 (1–4)	2 (2–2)	0.629	0.629
Number needing cell saver solution	83 (58.0%)	61 (56.5%)	52 (60.5%)	22 (62.9%)	0.542	0.840
-Volume (mL)	504 (300–1016)	521 (483–1016)	501 (292–1030)	500 (280–747)	0.248	0.248
Number needing Trasylol	17 (11.9%)	10 (9.3%)	9 (10.5%)	7 (20.0%)	0.092	0.234
<b>Primary graft non-function</b>	5 (3.4%)	4 (3.7%)	3 (3.5%)	1 (2.9%)	1.000	1.000
<b>Bile leaks</b>	13 (9.1%)	7 (6.5%)	5 (5.8%)	6 (17.1%)	0.085	0.077
<b>Acute kidney injury</b>						
Risk (or above)	76 (53.1%)	53 (49.1%)	47 (54.7%)	23 (65.7%)	0.082	0.233
Injury (or above)	49 (34.2%)	34 (32.4%)	30 (34.9%)	15 (42.9%)	0.229	0.410
Failure	21 (14.7%)	13 (12.0%)	11 (12.8%)	8 (22.9%)	0.168	0.172
Number needing RRT	21 (14.7%)	16 (14.8)	15 (17.0%)	5 (14.3%)	0.923	0.793
-Days RRT needed	5 (3–11)	7 (3–14)	8 (4–15)	5 (4–8)	0.491	0.284
<b>Days of hospital stay</b>	10 (8–14)	10 (8–13)	10 (8–14)	9 (7–16)	0.768	0.794
Days on ICU	2 (2–4)	3 (2–4)	3 (2–4)	2 (2–3)	0.251	0.198
Days requiring invasive ventilation	1 (1–1)	1 (1–2)	1 (1–2)	1 (1–1)	0.064	0.106

\* Denotes statistical comparisons between all DBD vs. DCD liver transplants in PSC patients

\*\* Denotes statistical comparisons between only whole liver DBD grafts vs. DCD transplants in PSC patients

Data presented as median (IQR) for continuous variables and number (%) for categorical variables. AKI, acute kidney injury; FFP, fresh frozen plasma; ICU, intensive care unit; RRT, renal replacement therapy.



**Table 2: Overall patient and graft survival following liver transplantation in PSC**

	<b>All patients</b> (n=143)	<b>DBD</b> All grafts (n=108)	<b>DBD</b> Non-split grafts (n=86)	<b>DCD</b> (n=35)	<i>p</i> *	<i>p</i> **
<b>Patient mortality/graft loss overall</b>						
-Cumulative number of events	34 (23.8%)	25 (23.1%)	20 (23.3%)	9 (25.8%)		
<b>-1-year event-free survival rate</b>	<b>86%</b>	<b>87%</b>	<b>87%</b>	<b>84%</b>	<b>0.450</b>	<b>0.427</b>
-Incidence rate per-100-pt.-yrs. (95% C.I.)	7.5 (6.6–8.8)	6.9 (6.1–8.4)	7.4 (6.2–9.0)	9.4 (7.1–13.9)	0.582 ***	0.586 ***
<b>Mortality only</b>						
-Cumulative number of events	22 (15.4%)	18 (16.7%)	15 (17.4%)	4 (11.4%)		
<b>-1-year event-free survival rate</b>	<b>90%</b>	<b>90%</b>	<b>90%</b>	<b>89%</b>	<b>0.228</b>	<b>0.183</b>
-Incidence rate per-100-pt.-yrs. (95% C.I.)	4.5 (4.0–5.2)	<b>4.7 (3.7–6.4)</b>	<b>5.4 (4.5–6.5)</b>	3.9 (3.0–5.4)	0.597 ***	0.454 ***
<b>Graft loss only</b>						
-Cumulative number of events	16 (11.1%)	11 (10.2%)	7 (8.1%)	5 (14.2%)		
<b>-1-year event-free survival rate</b>	<b>95%</b>	<b>95%</b>	<b>96%</b>	<b>94%</b>	<b>0.113</b>	<b>0.041</b>
-Incidence rate per-100-pt.-yrs. (95% C.I.)	3.6 (3.1–4.2)	<b>3.1 (2.7–3.7)</b>	<b>2.6 (2.2 – 3.2)</b>	5.2 (3.7–7.7)	0.336 ***	0.170 ***

\* Denotes statistical comparisons between all DBD vs. DCD liver transplants in PSC patients

\*\* Denotes statistical comparisons between only whole liver DBD grafts vs. DCD transplants in PSC patients

\*\*\* Statistical differences in the clinical event rate between groups assessed by the log rank test (time-dependent endpoints)

**Table 3: Patient and graft survival in PSC versus non-PSC liver transplantation**

Patient group	Mortality	Graft loss	Graft loss or mortality
<b>A) Incidence rates *</b>			
PSC (all)	4.5 (4.0–5.2)	3.6 (3.1–4.2)	7.5 (6.6–8.8)
PSC DBD	4.7 (3.7–6.4)	3.1 (2.7–3.7)	6.9 (6.1– 8.4)
PSC DBD (Non-split grafts)	5.4 (4.5 – 6.5)	2.6 (2.2–3.2)	7.4 (6.2–9.0)
PSC DCD	3.9 (3.0–5.4)	5.3 (4.0–7.7)	9.4 (7.1–13.9)
Non-PSC (all)	5.6 (5.0–6.3)	1.4 (1.4–1.5)	6.5 (6.2–6.8)
Non-PSC DBD	5.3 (5.0–5.6)	1.3 (1.2–1.4)	6.3 (5.9–6.7)
Non-PSC DCD	7.2 (6.4–8.1)	1.7 (1.6–2.0)	8.9 (7.9–10.0)
<b>B) Risk **</b>			
PSC DCD vs. PSC DBD	0.75 (0.25–2.21) <i>p</i> =0.598	1.69 (0.58–4.95) <i>p</i> =0.341	1.24 (0.56–2.66) <i>p</i> =0.583
PSC DCD vs. PSC DBD (Non-split grafts)	0.66 (0.22–1.99) <i>p</i> =0.458	2.25 (0.68–7.40) <i>p</i> =0.182	1.25 (0.56–2.76) <i>p</i> =0.587
PSC vs. non-PSC (all)	1.30 (0.84–2.03) <i>p</i> =0.239	2.30 (1.30–4.08) <i>p</i> =0.004	0.94 (0.65–1.34) <i>p</i> =0.716
PSC DCD vs. non-PSC DCD	0.57 (0.20–1.58) <i>p</i> =0.278	3.11 (1.04–9.32) <i>p</i> =0.043	1.11 (0.54–2.28) <i>p</i> =0.769
PSC DBD vs. non-PSC DBD	0.83 (0.51–1.35) <i>p</i> =0.451	2.05 (1.04–4.05) <i>p</i> =0.038	1.05 (0.69–1.59) <i>p</i> =0.819

\* Values presented per 100-patient-years with 95% confidence intervals in parenthesis.

\*\* Values presented as hazard ratios with 95% confidence intervals in parenthesis.

**Figure 1: Non-anastomotic biliary strictures post liver transplantation (PSC)**

The incidence of non-anastomotic biliary stricturing disease post liver transplantation for PSC is shown for all transplant recipients in [A], and excluding split liver grafts in [B]. Hazard ratios for DCD vs. DBD groups: 1.33 (95% CI: 0.53 – 3.38)  $p=0.540$  and 1.25 (95% CI: 0.48 – 3.26)  $p = 0.648$ , for [A] and [B], respectively. Non-anastomotic strictures have been included when they occur in the absence of ABO incompatibility, chronic rejection and hepatic artery compromise. P values determined via log-rank testing.

**Figure 2: Biliary stricturing disease following liver transplantation in PSC**

Kaplan-Meier survivorship estimates illustrating the incidence of post-transplant biliary strictures stratified by donor type. The overall incidence of all biliary strictures is shown in [A], and more specifically with ischaemic-type biliary strictures (ITBL) [B], anastomotic strictures [C] and lesions in keeping with recurrent PSC [D]. P values determined via log-rank testing.

**Figure 3: Biliary stricturing disease following liver transplantation in PSC  
excluding split liver grafts**

Kaplan-Meier survivorship estimates illustrating the incidence of post-transplant biliary strictures stratified by donor type and excluding split liver grafts. The overall incidence of all biliary strictures is shown in [A], and more specifically for ischaemic-type biliary strictures (ITBL) [B], anastomotic strictures [C] and lesions in keeping with recurrent PSC [D]. P values determined via log-rank testing.

**Figure 4: Clinical course following liver transplantation in PSC stratified by donor type**

Kaplan-Meier survivorship estimates illustrating the incidence of primary endpoints stratified by donor type. [A – C] indicate all liver transplants, and [D – F] represent exclusion of split liver grafts. Clinical events specified as [A] and [D] all-cause mortality, [B] and [E] as graft loss (patients censored at last date of follow-up, or at time of death free of re-transplantation); and [C] and [F] indicating graft loss or all-cause patient mortality combined. P values determined via log-rank testing.

Figure 1




Figure 2






Figure 3






Figure 4



## DCD vs. DBD Liver Transplantation for PSC



**Donation after circulatory death liver transplantation does not impact patient or graft survival in primary sclerosing cholangitis**

- The impact of liver donation after circulatory death (DCD) in transplantation for primary sclerosing cholangitis was prospectively evaluated.
- Operating time, days requiring critical care support, total ventilator days, incidence of acute kidney injury, need for renal replacement therapy (RRT) or total days requiring RRT were no different between DCD recipients vs. those receiving a liver donated after brain death (DBD).
- **DCD vs. DBD transplantation is not associated with increased risk of hepatic artery thrombosis or non-anastomotic biliary strictures (NAS) overall; however results in an increased incidence of ischaemic-type biliary lesions (ITBL) in the first year.**
- The risk of hepatic artery thrombosis is greatest in PSC patients with inflammatory bowel disease.
- Patient and graft survival is not significantly different for transplanted PSC patients receiving a DCD vs. DBD liver.